ascopubs.org

A randomized, double-blind, placebo-controlled phase II study of adjuvant pembrolizumab versus placebo in patients with head and neck squamous cell cancers at high risk for ...

Intra-treatment hypoxia directed major radiation de-escalation as definitive treatment for human papillomavirus-related oropharyngeal cancer. This is an ASCO Meeting Abstract from the 2024 ASCO Annual ...

Klothea Bio Announces the Launch of a Phase 1b Clinical Trial of AKL003, an Alpha Klotho mRNA Therapeutic, for the Extension of Human Lifespan

Klothea Bio, Inc. (“Klothea Bio”), a clinical-stage biotechnology company developing therapeutics based on their proprietary serum klotho platform, today announced the launch of a randomized, ...
ascopubs.org

Journal of Clinical Oncology

Hand-foot syndrome (HFS) is a dose-limiting side effect of capecitabine. Celecoxib prevents HFS by inhibiting cyclooxygenase-2 (COX-2) that is upregulated because of the underlying associated ...
TMCnet

Independent Data Monitoring Committee Recommends Initiation of Cohort 2 at the Increased Dose of 12 mg/kg in Entrada Therapeutics' ELEVATE-44-201 Study

-- Company on track to report ELEVATE-44-201 Cohort 1 data in Q2 2026, with Cohort 2 data by end of year -- ...